Company news
20/20 Biolabs, Inc. (NASDAQ:AIDX) news
20/20 Biolabs, Inc. news releases on 6ix. Latest, Oct 2, 2026: 20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Press releases & updates
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
October 2, 2026
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
October 1, 2026
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
September 29, 2026
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
September 28, 2026
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
August 28, 2026
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
August 26, 2026
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
August 17, 2026
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
July 30, 2026
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
July 27, 2026
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
July 23, 2026
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
July 9, 2026
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
June 22, 2026
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
May 27, 2026
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
May 22, 2026
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
May 20, 2026
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
May 14, 2026
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
May 12, 2026
HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
April 6, 2026
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
March 30, 2026
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
March 27, 2026
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
March 23, 2026
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
March 12, 2026
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
February 25, 2026
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
February 20, 2026
20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth
February 19, 2026